133 related articles for article (PubMed ID: 11951812)
1. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid.
Evans JL; Heymann CJ; Goldfine ID; Gavin LA
Endocr Pract; 2002; 8(1):29-35. PubMed ID: 11951812
[TBL] [Abstract][Full Text] [Related]
2. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
3. The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse JB
Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
[TBL] [Abstract][Full Text] [Related]
4. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
5. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
6. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
[TBL] [Abstract][Full Text] [Related]
7. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
8. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
Gavin LA; Barth J; Arnold D; Shaw R
Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
[TBL] [Abstract][Full Text] [Related]
10. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
11. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
Garber AJ
Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
[No Abstract] [Full Text] [Related]
12. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
Fonseca V; Foyt HL; Shen K; Whitcomb R
Diabetes Care; 2000 Mar; 23(3):354-9. PubMed ID: 10868865
[TBL] [Abstract][Full Text] [Related]
13. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
Kuzuya T; Iwamoto Y; Kosaka K; Takebe K; Yamanouchi T; Kasuga M; Kajinuma H; Akanuma Y; Yoshida S; Shigeta Y
Diabetes Res Clin Pract; 1991 Mar; 11(3):147-53. PubMed ID: 2036936
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic therapy for type 2 diabetes mellitus.
DeFronzo RA
Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
19. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Phillips SA; Ciaraldi TP; Kong AP; Bandukwala R; Aroda V; Carter L; Baxi S; Mudaliar SR; Henry RR
Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
Kirk JK; Pearce KA; Michielutte R; Summerson JH
J Fam Pract; 1999 Nov; 48(11):879-82. PubMed ID: 10907625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]